Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | RPA1 | P27694 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154424 | 0.84 | MCL1 (0.55) | MCL1MAPTALDH1A1HPGDSCN9A | |
| SCHEMBL4271936 | 0.83 | NPC1 (0.55) | MCL1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL1111239 | 0.83 | P2RY12 (0.52) | MCL1PDE10A | |
| SCHEMBL29660341 | 0.83 | MCL1 (0.76) | MCL1KMT2AMAPTADORA3ALDH1A1 | |
| SCHEMBL9619442 | 0.82 | MEN1 (0.64) | MEN1KMT2AMAPTTSHRATM | |
| SCHEMBL2928253 | 0.82 | MCL1 (0.66) | MCL1MAPTATMADORA3RPA1 | |
| SCHEMBL11149772 | 0.82 | ALDH1A1 (0.57) | MCL1MEN1KMT2AMAPTADORA3 | |
| SCHEMBL11155810 | 0.82 | MCL1 (0.63) | MCL1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3131606 | 0.82 | MCL1 (0.65) | MCL1PLA2G2ASCN9A | |
| SCHEMBL11149723 | 0.81 | MAPT (0.54) | MCL1MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058263-B2 | Substituted 2-phenyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-24 | — | — | US | disclosed |
| EP-2279191-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009125366-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | P2RY12, P2RY13, P2RY11 | MCL1 2710/4885MEN1 3005/4885KMT2A 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.